Online inquiry

IVTScrip™ mRNA-Anti-CD3E&MS4A1, CD20-TCB (2:1)(Cap 0, 5-Methyl-CTP & Pseudo-UTP, 30 nt-poly(A))   (CAT#: GTTS-WQ5317MR)

This product GTTS-WQ5317MR is a type of mRNA having 30 nt poly(A) tail and modified with Cap 0 & 5-Methyl-CTP & Pseudo-UTP. It ecodes the monoclonal antibody that targets CD3E&MS4A1 gene. The antibody can be applied in Lymphoma, B cell research.
Specifications
Product type mRNA
Modified bases 5-Methyl-CTP & Pseudo-UTP
5' Cap Cap 0
Species Humanized
RefSeq NM_000733.4; NM_021950.4
Applications Gene therapy research
Format Powder
Quantity 100 µg
Purification oligo-dT affinity purification
Target Gene
Gene ID 916; 931
UniProt ID P07766; P11836
Download
Download resources about mRNA therapeutics development to boost your research.
CUSTOMER REVIEWS and Q&As

There are currently no Customer reviews or questions for IVTScrip™ mRNA-Anti-CD3E&MS4A1, CD20-TCB (2:1)(Cap 0, 5-Methyl-CTP & Pseudo-UTP, 30 nt-poly(A)) (GTTS-WQ5317MR). Click the button above to contact us or submit your feedback about this product.
See other products
CAT Product Name Product Type CDs
GTTS-WQ4530MR IVTScrip™ mRNA-Anti-PDCD1, BMS-936558(Cap 1, Pseudo-UTP, 120 nt-poly(A)) mRNA BMS-936558
GTTS-WQ7140MR IVTScrip™ mRNA-Anti-CTGF, FG-3019(Cap 1, 5-Methyl-CTP & Pseudo-UTP, 120 nt-poly(A)) mRNA FG-3019
GTTS-WQ7539MR IVTScrip™ mRNA-Anti-CLDN18, GC-182(Cap 0, 2-Thio-UTP, 120 nt-poly(A)) mRNA GC-182
GTTS-WQ5633MR IVTScrip™ mRNA-Anti-TNF, CDP870(Cap 0, N1-Methylpseudo-UTP, 30 nt-poly(A)) mRNA CDP870
GTTS-WQ7535MR IVTScrip™ mRNA-Anti-CLDN18, GC-182(Cap 0, Pseudo-UTP, 120 nt-poly(A)) mRNA GC-182
GTTS-WQ13248MR IVTScrip™ mRNA-Anti-PCSK9, PF-05335810(Cap 1, 2-Thio-UTP, 120 nt-poly(A)) mRNA PF-05335810
GTTS-WQ11354MR IVTScrip™ mRNA-Anti-CD19, MEDI-551(Cap 1, Pseudo-UTP, 120 nt-poly(A)) mRNA MEDI-551
GTTS-WQ4504MR IVTScrip™ mRNA-Anti-CXCL10, BMS-936557(Cap 1, N1-Methylpseudo-UTP, 120 nt-poly(A)) mRNA BMS-936557
All products and services are For Research Use Only and CANNOT be used in the treatment or diagnosis of disease.
webinar

EABR Nanoparticles as a Platform Technology for Hybrid mRNA Vaccine Development

November 20th, 2024, 2 PM–3 PM EST

REGISTER NOW